Thyroid Nodule Growth Calculator: Has Your Nodule Grown Significantly?
You had a thyroid ultrasound. Then you had another one a year or two later. Now you are staring at two reports with different numbers on them, and you want to know one thing: did my nodule grow enough to worry about?
The good news is the answer is usually no. Most benign thyroid nodules either stay the same size for years or grow so slowly that the change is meaningless. The bad news is that you can’t eyeball this. A 2 mm change sounds tiny, but on a small nodule it can mean a 40 percent volume increase, which is the threshold the American Thyroid Association uses to recommend repeat biopsy. This calculator does the math for you and tells you whether your specific change meets the ATA criteria for significant growth[1].
Here’s how to use it:
Enter the 3 dimensions and date from your earlier ultrasound, then enter the same from your later ultrasound. Add your original Bethesda category and TI-RADS score if you have them. The calculator returns your volume change, your per-dimension growth, your annual growth rate, and a clear yes-or-no answer on whether ATA significant growth criteria are met. If they are, you get a specific next-step recommendation based on your original biopsy or imaging history.
Note: This is a decision support tool, not a diagnosis. Your endocrinologist, radiologist, or thyroid surgeon makes the final call on whether your specific situation needs repeat biopsy or surgery. Bring the result to your appointment. Don’t make management decisions based on this calculator alone.
Thyroid Nodule Growth Calculator
Has your nodule grown significantly? Enter your before and after ultrasound measurements to see your volume change and whether your nodule meets the ATA significant growth criteria that warrant repeat biopsy or re-evaluation.
| Criterion | Definition | Clinical Meaning |
|---|---|---|
| Criterion A | More than 20% increase in at least 2 of 3 dimensions, AND minimum 2 mm absolute increase in those dimensions | More sensitive (catches subtle growth across multiple dimensions) |
| Criterion B | More than 50% increase in calculated nodule volume | More specific (catches substantial overall change) |
Either criterion met = significant growth. Volume is calculated using the standard ellipsoid formula: V = length × width × depth × 0.524.
Written and medically reviewed by Dr. Westin Childs, D.O. Last reviewed: May 11, 2026.
How to Use This Calculator
Step #1: Find Your Earlier Ultrasound Report
Pull up the first ultrasound report you want to compare. The date is usually at the top. The measurements look something like “1.2 x 0.8 x 0.7 cm” and refer to the length, width, and depth of the nodule. The order doesn’t matter for this calculator because it sorts them for you, so don’t worry about figuring out which number is which.
If you have multiple nodules on the report, pick the one your doctor is following. That’s usually labeled “dominant nodule” or has the most detailed feature description.
Step #2: Find Your Newer Ultrasound Report
Now pull up the more recent ultrasound. Make sure you’re comparing the same nodule. If your earlier report said “right lobe lower pole 1.2 x 0.8 x 0.7 cm,” your newer report should also reference the right lobe lower pole. If the locations don’t match, you may be looking at a different nodule, and the comparison won’t be valid.
Step #3: Enter Dimensions and Dates for Both Timepoints
Type each dimension into the matching field. Use centimeters. If your report is in millimeters, divide by 10 (so 15 mm = 1.5 cm). Add the dates of each ultrasound. The calculator uses the time between the two scans to compute your nodule’s annual growth rate, which is one of the most useful numbers your endocrinologist will want to see.
For reference, a benign thyroid nodule typically grows less than 2 mm per year. Faster growth than that doesn’t mean cancer (more on this below) but it does mean the nodule is worth watching more closely[2].
Step #4: Add Optional Context (Bethesda, TI-RADS)
If you’ve had a biopsy on this nodule, pick your Bethesda category from the dropdown. If you’ve only had ultrasound surveillance without a biopsy, pick “No FNA done.” The Bethesda category changes the next-step recommendation significantly. Significant growth on a Bethesda 2 (benign) nodule warrants repeat biopsy. Significant growth on a Bethesda 3 or 4 (indeterminate) nodule strengthens the case for molecular testing or surgery.
If you know your original TI-RADS score, add that too. If your nodule was TR3, TR4, or TR5 and it has now grown into a new size category, the calculator will tell you to re-score the nodule with the updated dimensions using the TI-RADS Calculator because FNA may now be indicated based on the new size threshold.
Step #5: Read Your Significant Growth Verdict
The calculator shows you everything in three parts. First, a side-by-side comparison of your two scans with the calculated volumes for each. Second, a dimension-by-dimension table showing how much each measurement changed and whether it meets the ATA Criterion A threshold. Third, a clear “Significant Growth: YES” or “Significant Growth: NO” verdict with the specific reasons cited.
If the verdict is YES, you’ll also see a recommendation banner tailored to your Bethesda or TI-RADS history. Bring this to your endocrinology appointment. Print it or screenshot it. You will save yourself 30 minutes of back-and-forth and walk in already knowing what the next step is.
Understanding Your Results
The ATA Significant Growth Criteria (A and B)
The 2015 American Thyroid Association Cancer Guidelines define significant nodule growth two ways[1]. Criterion A requires more than a 20 percent increase in at least 2 of 3 dimensions, plus a minimum 2 mm absolute increase in those dimensions. Criterion B requires more than a 50 percent increase in calculated volume. If your nodule meets either one, that’s significant growth by the standard your endocrinologist will use.
The reason there are two criteria is that small nodules and large nodules behave differently. A 1 mm growth on a 5 mm nodule is a 20 percent increase, which sounds like a lot but is well within ultrasound measurement error. The 2 mm absolute minimum on Criterion A prevents false positives on tiny nodules. Criterion B catches the cases where one dimension didn’t quite hit 20 percent but the total volume change is still substantial.
Why Dimension Order Doesn’t Matter
Different ultrasound techs write your nodule’s 3 dimensions in different orders. Sometimes it’s longest first. Sometimes it’s anteroposterior first. Sometimes it just depends on what view the tech took the measurement from. This means your earlier scan might list dimensions as 1.5 x 1.0 x 0.9 cm and your later scan might list the same nodule (with no actual change) as 1.0 x 1.5 x 0.9 cm.
If a calculator compared those numbers position by position, it would tell you the first dimension shrank by 33 percent and the second grew by 50 percent. That’s a false positive panic. This calculator handles it by sorting both sets of dimensions largest to smallest before doing any math. The output labels them “Largest, Middle, Smallest” so you can see what’s being compared. This isn’t a fancy feature, it’s how endocrinologists evaluate serial scans in the first place.
Growth Rate Context: What’s Normal?
Most benign thyroid nodules grow less than 2 mm per year on average[2]. The published natural history data divides nodule growth into three patterns. Stagnant nodules (less than 0.2 mm per year) make up the majority. Slow-growing nodules (0.2 to 1.0 mm per year) are also common and almost always benign. Fast-growing nodules (more than 1.0 mm per year) represent about 17 percent of the cohort and are more common in patients younger than 50 and in larger nodules.
Here’s the thing most patients miss: even rapid growth is not a marker for cancer[3]. Multiple studies have shown that benign nodules and malignant nodules can grow at similar rates, and benign nodules sometimes grow faster than malignant ones. Growth alone doesn’t diagnose cancer. It just tells you the nodule is changing, which is the trigger for the next step (usually repeat biopsy or repeat ultrasound surveillance at a tighter interval).
Beyond the Numbers: The Functional Layer
If your nodule grew, the bigger question is why. Most nodule growth is driven by underlying thyroid inflammation, autoimmunity, or hormonal imbalance. Patients with elevated TPO antibodies and inadequately treated hypothyroidism have higher rates of nodule formation and faster growth than patients with optimized thyroid function. Even when cancer is ruled out, the underlying environment matters because it determines whether you’ll keep forming new nodules over the next decade.
I treat the underlying environment in my clinical practice using a combination of thyroid hormone optimization (sometimes adjusting medication based on free T3 rather than just TSH), antibody management for Hashimoto’s patients, and supplement support that targets thyroid inflammation. Want to assess your own thyroid environment? Check your labs against optimal ranges with the Optimal Thyroid Lab Test Calculator, screen for autoimmune thyroiditis with the Hashimoto’s Symptom Quiz, or read the full guide to thyroid nodules for the natural and medical treatment options.
Frequently Asked Questions
The 2015 American Thyroid Association Cancer Guidelines give us two ways to measure significant growth and either one counts[1]. The first is a more than 20 percent increase in at least 2 of the 3 nodule dimensions, with a minimum 2 mm absolute increase in those dimensions. The second is a more than 50 percent increase in nodule volume. Volume is calculated using the standard ellipsoid formula (length times width times depth times 0.524).
Both criteria exist for a reason. The dimension-based criterion catches subtle growth across multiple measurements. The volume criterion catches cases where one dimension didn’t quite hit 20 percent but the total size change is still substantial. If your nodule meets either, your endocrinologist will likely recommend repeat biopsy or closer surveillance depending on the original Bethesda category and your individual risk factors.
It depends on which dimensions grew and by how much in absolute terms. A 20 percent increase in one dimension alone doesn’t meet the ATA significant growth threshold. You need a 20 percent increase in at least 2 of the 3 dimensions, AND each of those dimensions has to also grow by at least 2 mm in absolute size[1]. The 2 mm minimum exists because ultrasound measurement error is roughly 1 to 2 mm, so a tiny percent change without enough absolute size change might just be measurement noise.
If your nodule meets that combined threshold in 2 of 3 dimensions, OR your overall volume increased by more than 50 percent, that’s a significant change worth re-evaluating. The next step depends on your original FNA biopsy result if you had one. If you’ve never had a biopsy and your nodule has grown into a new TI-RADS size category, you may now meet the threshold for FNA. Run the new measurements through the TI-RADS Calculator to see.
Most benign thyroid nodules grow less than 2 mm per year on average[2]. The published natural history data divides growth into three patterns. About 80 percent of nodules are stagnant (less than 0.2 mm per year). Slow-growers (0.2 to 1.0 mm per year) account for most of the rest and are almost always benign. Fast-growers (more than 1.0 mm per year) represent about 17 percent of nodules and are more common in patients under 50 and in larger nodules.
The biggest takeaway is that growth is normal. Almost all benign nodules change size at least a little over the years. The question isn’t whether your nodule grew, it’s whether it grew enough to cross the ATA significant growth threshold. That’s why the math matters more than the gut reaction to seeing different numbers on two reports.
No. This is the most important misconception to clear up. Rapid thyroid nodule growth is NOT a reliable marker for cancer. A 2015 study in the Journal of Clinical Endocrinology & Metabolism specifically looked at this question and found that benign nodules and malignant nodules can grow at similar rates, and benign nodules sometimes grow faster than malignant ones[3].
What rapid growth actually tells you is that something is driving the nodule to change. That something can be inflammation, autoimmune attack, hormonal stimulation (TSH), or yes, occasionally cancer. The point of the ATA significant growth threshold isn’t to identify cancer directly. It’s to identify which nodules need to go back through the diagnostic pipeline (repeat FNA, molecular testing, sometimes surgery) so cancer doesn’t get missed in the small percentage of cases where it’s present.
If your nodule has grown significantly, don’t panic. Get evaluated. Even with significant growth, the odds are still in your favor that the nodule is benign.
The 2015 ATA guidelines recommend repeat FNA biopsy if a previously benign (Bethesda 2) nodule meets significant growth criteria on follow-up imaging[1]. This may sound aggressive given that your first biopsy already said benign, but here’s the reasoning: every FNA carries a small sampling error risk. A single biopsy samples a tiny fraction of the nodule, so it’s possible the area with concerning cells was missed the first time. If the nodule then grows significantly, the chance that the original biopsy missed something goes up, and a repeat biopsy is the safest way to confirm the nodule is still benign.
If you’ve had two prior benign biopsies and the nodule is still growing slowly, your endocrinologist may continue surveillance instead of doing a third biopsy. Two benign FNA results have a much lower combined false-negative rate than one. Discuss the specifics with your endocrinologist, including whether the growth rate is fast or slow and whether any new suspicious features have appeared on the latest ultrasound. The decision isn’t automatic, it depends on your full clinical picture.
It depends on your nodule’s risk profile from the original ultrasound. The 2015 ATA guidelines recommend follow-up intervals based on the sonographic pattern. High-suspicion nodules with benign FNA get repeat ultrasound within 12 months. Low and intermediate suspicion nodules can be checked every 12 to 24 months. Very low suspicion or benign-appearing nodules over 1 cm can be re-imaged in 24 months or more, and small benign-appearing nodules may not need routine ultrasound surveillance at all[1].
If you don’t remember what your radiologist or endocrinologist recommended, look at the ultrasound report itself. Most reports include a recommended follow-up interval in the impression section. If they don’t, call your endocrinologist’s office and ask. Don’t go longer than 24 months without a follow-up if you have an established nodule over 1 cm, even if your last scan was reassuring.
References
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. https://www.liebertpub.com/doi/10.1089/thy.2015.0020
- Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA. 2015;313(9):926-935. https://jamanetwork.com/journals/jama/fullarticle/2174711
- Angell TE, Vyas CM, Medici M, et al. Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. Journal of Clinical Endocrinology & Metabolism. 2017;102(12):4642-4647. https://academic.oup.com/jcem/article/102/12/4642/4460058
- Brunese L, Romeo A, Iorio S, et al. Thyroid B-flow twinkling sign: a new feature of papillary cancer. European Journal of Endocrinology. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC4683761/
- American Thyroid Association. Change in Thyroid Nodule Volume Calculator. ATA Professionals Tools. https://www.thyroid.org/professionals/calculators/thyroid-with-nodules/
- Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-1346. https://www.liebertpub.com/doi/10.1089/thy.2017.0500
- Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. Journal of the American College of Radiology. 2017;14(5):587-595. https://www.jacr.org/article/S1546-1440(17)30186-1/fulltext